Next Article in Journal
Effects of Quercetin in a Rat Model of Hemorrhagic Traumatic Shock and Reperfusion
Next Article in Special Issue
The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
Previous Article in Journal
Natural Products in Anti-Obesity Therapy
Previous Article in Special Issue
Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Molecules 2016, 21(12), 1748; doi:10.3390/molecules21121748

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

1
Laboratoire de la barrière hémato-encéphalique (LBHE), University Artois, EA 2465, Lens, F-62300, France
2
Unité de Catalyse et de Chimie du Solide (UCCS), University Artois, CNRS, UMR 8181, Lens, F-62300, France
3
ROQUETTE, Nutrition & Health R & D, 62136 Lestrem, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Bernard Martel
Received: 9 November 2016 / Revised: 13 December 2016 / Accepted: 14 December 2016 / Published: 20 December 2016
(This article belongs to the Special Issue Cyclodextrin Chemistry)
View Full-Text   |   Download PDF [1510 KB, uploaded 20 December 2016]   |  

Abstract

Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE® CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer’s, Parkinson’s and Huntington’s diseases are currently on-going. View Full-Text
Keywords: cyclodextrins; cholesterol; atherosclerosis; neurodegenerative diseases; vascular diseases; Niemann-Pick disease type C (NPC); Alzheimer’s disease (AD); blood-brain barrier (BBB); HPβCD; KLEPTOSE® CRYSMEB cyclodextrins; cholesterol; atherosclerosis; neurodegenerative diseases; vascular diseases; Niemann-Pick disease type C (NPC); Alzheimer’s disease (AD); blood-brain barrier (BBB); HPβCD; KLEPTOSE® CRYSMEB
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Coisne, C.; Tilloy, S.; Monflier, E.; Wils, D.; Fenart, L.; Gosselet, F. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules 2016, 21, 1748.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top